525
Views
23
CrossRef citations to date
0
Altmetric
Original Research

Atypical antipsychotics for Parkinson’s disease psychosis: a systematic review and meta-analysis

, , , , , & show all
Pages 2137-2149 | Published online: 29 Jul 2019

References

  • Palacios-Sanchez L, Torres Nupan M, Botero-Meneses JS. James Parkinson and his essay on “shaking palsy”, two hundred years later. Arq Neuropsiquiatr. 2017;75:671–672. doi:10.1590/0004-282X2017010828977149
  • de Lau LML, Breteler MMB. Epidemiology of Parkinson’s disease. Lancet Neurol. 2006;5:525–535. doi:10.1016/S1474-4422(06)70471-916713924
  • Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68:384–386. doi:10.1212/01.wnl.0000247740.47667.0317082464
  • Markham A. Pimavanserin: first global approval. Drugs. 2016;76:1053–1057. doi:10.1007/s40265-016-0597-927262680
  • Friedman JH. Parkinson disease psychosis: update. Behav Neurol. 2013;27:469–477. doi:10.3233/BEN-12901623242358
  • Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson’s disease: report of an NINDS, NIMH work group. Mov Disord. 2007;22:1061–1068. doi:10.1002/mds.2138217266092
  • Cruz MP. Pimavanserin (Nuplazid): a treatment for hallucinations and delusions associated with Parkinson’s disease. P T. 2017;42:368–371.28579723
  • Hermanowicz N, Edwards K. Parkinson’s disease psychosis: symptoms, management, and economic burden. Am J Manag Care. 2015;21:s199–s206.26296199
  • Goldman JG, Vaughan CL, Goetz CG. An update expert opinion on management and research strategies in Parkinson’s disease psychosis. Expert Opin Pharmacother. 2011;12:2009–2024. doi:10.1517/14656566.2011.58712221635198
  • Hermanowicz N, Alva G, Pagan F, et al. The emerging role of pimavanserin in the management of Parkinson’s disease psychosis. J Managed Care Specialty Pharm. 2017;23:S2–S8. doi:10.18553/jmcp.2017.23.6-b.s2
  • Divac N, Stojanovic R, Savic Vujovic K. The efficacy and safety of antipsychotic medications in the treatment of psychosis in patients with Parkinson’s disease. Behav Neurol. 2016;2016:4938154.
  • Lutz UC, Sirfy A, Wiatr G, et al. Clozapine serum concentrations in dopamimetic psychosis in Parkinson’s disease and related disorders. Eur J Clin Pharmacol. 2014;70:1471–1476. doi:10.1007/s00228-014-1772-025323805
  • Jethwa KD, Onalaja OA. Antipsychotics for the management of psychosis in Parkinson’s disease: systematic review and meta-analysis. B J Psych Open. 2015;1:27–33. doi:10.1192/bjpo.bp.115.000927
  • Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson’s disease: structured review and meta-analysis. Eur Neuropsychopharmacol. 2007;17:165–171. doi:10.1016/j.euroneuro.2006.08.00717070675
  • Yasue I, Matsunaga S, Kishi T, Fujita K, Iwata N. Serotonin 2A receptor inverse agonist as a treatment for Parkinson’s disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators. J Alzheimer’s Dis. 2016;50:733–740. doi:10.3233/JAD-15081826757194
  • Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ (Clinical Research Ed). 2009;339:b2700. doi:10.1136/bmj.b2651
  • Fan X, Lin T, Xu K, et al. Laparoendoscopic single-site nephrectomy compared with conventional laparoscopic nephrectomy: a systematic review and meta-analysis of comparative studies. Eur Urol. 2012;62:601–612. doi:10.1016/j.eururo.2012.05.05522704730
  • Sterne JAC, Egger M, Moher D. [homepage on the Internet]. Addressing reporting biases In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. New York: The Cochrane Collaboration; 2009 (Updated March 2011). Available from: http://www.cochrane-handbook.org. Accessed October 23, 2017.
  • Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13. doi:10.1186/1471-2288-5-2715840177
  • Wiebe N, Vandermeer B, Platt RW, Klassen TP, Moher D, Barrowman NJ. A systematic review identifies a lack of standardization in methods for handling missing variance data. J Clin Epidemiol. 2006;59:342–353. doi:10.1016/j.jclinepi.2005.08.01716549255
  • Da Costa BR, Nuesch E, Rutjes AW, et al. Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study. J Clin Epidemiol. 2013;66:847–855. doi:10.1016/j.jclinepi.2013.03.00923747228
  • Yuan M, Sperry L, Malhado-Chang N, et al. Atypical antipsychotic therapy in Parkinson’s disease psychosis: a retrospective study. Brain Behav. 2017;7:e00639. doi:10.1002/brb3.63928638698
  • Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533–540. doi:10.1016/S0140-6736(13)62106-624183563
  • Nichols MJ, Hartlein JM, Eicken MG, Racette BA, Black KJ. A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease. F1000 Res. 2013;2:150. doi:10.12688/f1000research
  • Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson’s disease psychosis. Neuropsychopharmacology. 2010;35:881–892. doi:10.1038/npp.2009.17619907417
  • Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease. Neuropsychiatr Dis Treat. 2009;5:327–332. doi:10.2147/ndt.s533519557142
  • Fernandez HH, Okun MS, Rodriguez RL, et al. Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study. Int J Neurosci. 2009;119:2196–2205. doi:10.3109/0020745090322275819916848
  • Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord. 2007;22:313–318. doi:10.1002/mds.2111617034006
  • Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord. 2005;20:958–963. doi:10.1002/mds.2047415800937
  • Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004;75:689–695. doi:10.1136/jnnp.2003.02986815090561
  • Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov Disord. 2002;17:1031–1035. doi:10.1002/mds.1021712360554
  • Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson’s disease. Biol Psychiatry. 2002;52:438–445.12242060
  • Parkinson Study G. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s disease. N Engl J Med. 1999;340:757–763. doi:10.1056/NEJM19990311340100310072410
  • NCT00658567. A study of safety and efficacy of pimavanserin (ACP-103) in patients with Parkinson’s disease psychosis; 2009 Available from: https://clinicaltrials.gov/ct2/show/NCT00658567.Accessed July 10, 2019.
  • NCT00477672. A study of the safety and efficacy of pimavanserin (acp-103) in patients with Parkinson’s disease phychosis; 2009 Available from: https://clinicaltrials.gov/ct2/show/NCT00477672. Accessed July 10, 2019.
  • Acadia Pharmaceuticals Inc. Prescribing Information for NuplazidTM (Pimavanserin) Tablets, for Oral Use; 2016 Available from: http://www.acadia-pharm.com/product/. Accessed 10 July 2019.
  • Maneeton B, Putthisri S, Maneeton N, et al. Quetiapine monotherapy versus placebo in the treatment of children and adolescents with bipolar depression: a systematic review and meta-analysis. Neuropsychiatr Dis Treat. 2017;13:1023–1032. doi:10.2147/NDT.S12151728435272
  • Mathis MV, Muoio BM, Andreason P, et al. The US Food and Drug Administration’s Perspective on the New Antipsychotic Pimavanserin. J Clin Psychiatry. 2017. doi:10.4088/JCP.16r11119
  • Fox SH. Pimavanserin as treatment for Parkinson’s disease psychosis. Lancet. 2014;383:494–496. doi:10.1016/S0140-6736(13)62157-124183566
  • Cummingsa J, Millsc R, Williamsc H, Chi-Burrisc K, Dhalld R, Ballarde C. Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson’s Disease psychosis (Acp-103-020). J Neurol Sci. 2013;333(Supplement 1):119–e120. doi:10.1016/j.jns.2013.07.401
  • Combs BL, Cox AG. Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin. Neuropsychiatr Dis Treat. 2017;13:737–744. doi:10.2147/NDT.S10894828331324
  • Duits JH, Ongering MS, Martens HJM, Schulte PFJ. [Pimavanserin: a new treatment for the Parkinson’s disease psychosis]. Tijdschr Psychiatr. 2017;59:528–536.28880354
  • Miyasaki JM, Shannon K, Voon V, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006;66:996–1002. doi:10.1212/01.wnl.0000215428.46057.3d16606910
  • Bozymski KM, Lowe DK, Pasternak KM, Gatesman TL, Crouse EL. Pimavanserin: a novel antipsychotic for Parkinson’s Disease psychosis. Ann Pharmacother. 2017;51:479–487. doi:10.1177/106002801769302928375643
  • Goldman JG, Holden S. Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol. 2014;16:281. doi:10.1007/s11940-013-0281-224464490